Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Authors not listed

Yale University · 2021

Abstract

This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2021). An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923. <em>Yale University</em>. https://clinicaltrials.gov/study/NCT04805983
Vancouver
Anonymous. An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923. Yale University. 2021.
BibTeX
@misc{anon2021AnOpen, title = {An Open-Label, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923}, author = {Anonymous}, journal = {Yale University}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings